Table 1.
Putative CSC marker | Putative CSCs identified | CSCs validated | Screened only (references) | Screened and validated (references) |
---|---|---|---|---|
CD133+ | 10 of 11 | 5 of 5 | [25, 27, 29–31] | [28, 32–35]* |
ALDH+ | 4 of 4 | 4 of 4 | [25, 27, 28, 33]* | |
HSP+ | 4 of 4 | 4 of 4 | [31, 36–38] | |
CD44+ | 12 of 12 | 1 of 2 | [27–32, 36, 39] | [33, 40] |
CD117+ | 7 of 11 | 1 of 2 | [33, 40] | |
CD24+ | 7 of 7 | 1 of 1 | [25, 28, 31, 32, 36] | [41] |
CD24- | 1 of 1 | 1 of 1 | [30] | |
ABCG2+ | 2 of 3 | 0 of 2 | [30] | [28, 38] |
This table is ranked from top to bottom by the most frequently validated ovarian CSC markers. CSC validation is classified as a demonstration of increased xenograft tumorigenicity in the respective studies. Most studies screened for multiple CSC markers, while only bringing a sub-set forward for validation. This table makes the distinction between markers that were ‘screened only’ and those that were ‘screened and validated’ in the respective studies.
*[33] found that CD133+ and ALDH+ putative CSCs validated as CSCs in most but not all of the patients tested. In other patients there was no significant difference between CD133+ and CD133- or ALDH+ and ALDH- cells in tumorigenicity. Additionally, in a small sub-set of patients CD133- not CD133+ cells were identified as CSCs.